Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS:
Long acting natriuretic peptide, vessel dilator, kaliuretic peptide, atrial natriuretic peptide and urodilatin eliminated 86%, 71%, 57%, 43% (P < 0.001 for the cardiac hormones) and 25% (P < 0.05; urodilatin) of the human small-cell lung carcinomas. The treated small-cell lung carcinomas that were not cured grew rapidly, similar to the untreated controls, whose volume was 7 fold larger in 1 week, 18-fold increased in 2 weeks, 39-fold increased in 3 weeks, 63-fold increased in 1 month and 97-fold increased in volume in 6 weeks. One vessel dilator treated small-cell lung carcinoma animal developed a large tumour (8428 mm3 volume) on treatment and this tumour was eliminated with utilizing atrial natriuretic peptide and then long acting natriuretic peptide sequentially. CONCLUSIONS:
|
Authors | E J Eichelbaum, Y Sun, A A Alli, W R Gower Jr, D L Vesely |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 38
Issue 8
Pg. 562-70
(Aug 2008)
ISSN: 1365-2362 [Electronic] England |
PMID | 18717826
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Peptide Fragments
- Protein Precursors
- atrial natriuretic factor precursor (79-98)
- atrial natriuretic factor prohormone (1-30), human
- atrial natriuretic factor prohormone (31-67)
- Ularitide
- Atrial Natriuretic Factor
- Receptors, Atrial Natriuretic Factor
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Atrial Natriuretic Factor
(therapeutic use)
- Carcinoma, Small Cell
(drug therapy, pathology)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Mice
- Mice, Nude
- Neoplasm Metastasis
(drug therapy)
- Peptide Fragments
(therapeutic use)
- Protein Precursors
(therapeutic use)
- Receptors, Atrial Natriuretic Factor
(analysis)
|